FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1791492057> ?p ?o ?g. }

• W1791492057 abstract "Insomnia is a major public health issue affecting between 6% to 10% of the adult population in Western countries. Eszopiclone is a hypnotic drug belonging to a newer group of hypnotic agents, known as new generation hypnotics, which was marketed as being just as effective as benzodiazepines for this condition, while being safer and having a lower risk for abuse and dependence. It is the aim of the review to integrate evidence from randomised controlled trials and to draw conclusions on eszopiclone's efficacy and safety profile, while taking methodological features and bias risks into consideration.To assess the efficacy and safety of eszopiclone for the treatment of insomnia compared to placebo or active control.We searched the Cochrane Central Register of Controlled trials (CENTRAL), MEDLINE, Embase, PsycINFO, PSYNDEX and registry databases (WHO trials portal, ClinicalTrials.gov) with results incorporated from searches to 10 February 2016. To identify trials not registered in electronic databases, we contacted key informants and searched reference lists of identified studies. We ran an update search (21 February 2018) and have placed studies of interest in awaiting classification/ongoing studies. These will be incorporated into the next version of the review, as appropriate.Parallel group randomised controlled trials (RCTs) comparing eszopiclone with either placebo or active control were included in the review. Participants were adults with insomnia, as diagnosed with a standardised diagnostic system, including primary insomnia and comorbid insomnia.Two authors independently extracted outcome data; one reviewer assessed trial quality and the second author cross-checked it.A total of 14 RCTs, with 4732 participants, were included in this review covering short-term (≤ 4 weeks; 6 studies), medium-term (> 4 weeks ≤ 6 months; 6 studies) and long-term treatment (> 6 months; 2 studies) with eszopiclone. Most RCTs included in the review included participants aged between 18 and 64 years, three RCTs only included elderly participants (64 to 85 years) and one RCT included participants with a broader age range (35 to 85 years). Seven studies considered primary insomnia; the remaining studies considered secondary insomnia comorbid with depression (2), generalised anxiety (1), back pain (1), Parkinson's disease (1), rheumatoid arthritis (1) and menopausal transition (1).Meta-analytic integrations of participant-reported data on sleep efficacy outcomes demonstrated better results for eszopiclone compared to placebo: a 12-minute decrease of sleep onset latency (mean difference (MD) -11.94 min, 95% confidence interval (CI) -16.03 to -7.86; 9 studies, 2890 participants, moderate quality evidence), a 17-minute decrease of wake time after sleep onset (MD -17.02 min, 95% CI -24.89 to -9.15; 8 studies, 2295 participants, moderate quality evidence) and a 28-minute increase of total sleep time (MD 27.70 min, 95% CI 20.30 to 35.09; 10 studies, 2965 participants, moderate quality evidence). There were no significant changes from baseline to the first three nights after drug discontinuation for sleep onset latency (MD 17.00 min, 95% CI -4.29 to 38.29; 1 study, 291 participants, low quality evidence) and wake time after sleep onset (MD -6.71 min, 95% CI -21.25 to 7.83; 1 study, 291 participants, low quality evidence). Adverse events during treatment that were documented more frequently under eszopiclone compared to placebo included unpleasant taste (risk difference (RD) 0.18, 95% CI 0.14 to 0.21; 9 studies, 3787 participants), dry mouth (RD 0.04, 95% CI 0.02 to 0.06; 6 studies, 2802 participants), somnolence (RD 0.04, 95% CI 0.02 to 0.06; 8 studies, 3532 participants) and dizziness (RD 0.03, 95% CI 0.01 to 0.05; 7 studies, 2933 participants). According to the GRADE criteria, evidence was rated as being of moderate quality for sleep efficacy outcomes and adverse events and of low quality for rebound effects and next-day functioning.Eszopiclone appears to be an efficient drug with moderate effects on sleep onset and maintenance. There was no or little evidence of harm if taken as recommended. However, as certain patient subgroups were underrepresented in RCTs included in the review, findings might not have displayed the entire spectrum of possible adverse events. Further, increased caution is required in elderly individuals with cognitive and motor impairments and individuals who are at increased risk of using eszopiclone in a non-recommended way." @default.
• W1791492057 created "2016-06-24" @default.
• W1791492057 creator A5016086834 @default.
• W1791492057 creator A5020498004 @default.
• W1791492057 creator A5028591621 @default.
• W1791492057 creator A5071697628 @default.
• W1791492057 creator A5086769985 @default.
• W1791492057 date "2018-10-10" @default.
• W1791492057 modified "2023-10-16" @default.
• W1791492057 title "Eszopiclone for insomnia" @default.
• W1791492057 cites W116296003 @default.
• W1791492057 cites W147714449 @default.
• W1791492057 cites W1509748757 @default.
• W1791492057 cites W1529301134 @default.
• W1791492057 cites W1537972189 @default.
• W1791492057 cites W1548499812 @default.
• W1791492057 cites W1555600854 @default.
• W1791492057 cites W1594040463 @default.
• W1791492057 cites W1610957450 @default.
• W1791492057 cites W1754761839 @default.
• W1791492057 cites W178257240 @default.
• W1791492057 cites W179114280 @default.
• W1791492057 cites W1791492057 @default.
• W1791492057 cites W1814964269 @default.
• W1791492057 cites W1837742065 @default.
• W1791492057 cites W187579988 @default.
• W1791492057 cites W1935738678 @default.
• W1791492057 cites W1965476565 @default.
• W1791492057 cites W1965622047 @default.
• W1791492057 cites W1966792529 @default.
• W1791492057 cites W1971575090 @default.
• W1791492057 cites W1973735623 @default.
• W1791492057 cites W1974089925 @default.
• W1791492057 cites W1974414958 @default.
• W1791492057 cites W1974461787 @default.
• W1791492057 cites W1974600523 @default.
• W1791492057 cites W1974879176 @default.
• W1791492057 cites W1976498273 @default.
• W1791492057 cites W1977567122 @default.
• W1791492057 cites W1977894152 @default.
• W1791492057 cites W1978925858 @default.
• W1791492057 cites W1985315015 @default.
• W1791492057 cites W1986188642 @default.
• W1791492057 cites W1988943101 @default.
• W1791492057 cites W1990161259 @default.
• W1791492057 cites W1992903256 @default.
• W1791492057 cites W1993142933 @default.
• W1791492057 cites W1993926377 @default.
• W1791492057 cites W1994316908 @default.
• W1791492057 cites W1996244825 @default.
• W1791492057 cites W1997889941 @default.
• W1791492057 cites W2000979605 @default.
• W1791492057 cites W2001480478 @default.
• W1791492057 cites W2002669039 @default.
• W1791492057 cites W2006237636 @default.
• W1791492057 cites W2008023699 @default.
• W1791492057 cites W2008821456 @default.
• W1791492057 cites W2009845727 @default.
• W1791492057 cites W2011834030 @default.
• W1791492057 cites W2011870473 @default.
• W1791492057 cites W2012980780 @default.
• W1791492057 cites W2013775967 @default.
• W1791492057 cites W2014880231 @default.
• W1791492057 cites W2016332473 @default.
• W1791492057 cites W2016646738 @default.
• W1791492057 cites W2016652516 @default.
• W1791492057 cites W2017226579 @default.
• W1791492057 cites W2017415119 @default.
• W1791492057 cites W2020554589 @default.
• W1791492057 cites W2023944666 @default.
• W1791492057 cites W2024111201 @default.
• W1791492057 cites W2029771261 @default.
• W1791492057 cites W2030710544 @default.
• W1791492057 cites W2030865264 @default.
• W1791492057 cites W2034993534 @default.
• W1791492057 cites W2035240111 @default.
• W1791492057 cites W2037377025 @default.
• W1791492057 cites W2038537304 @default.
• W1791492057 cites W2038982658 @default.
• W1791492057 cites W2040749672 @default.
• W1791492057 cites W2041130859 @default.
• W1791492057 cites W2043451114 @default.
• W1791492057 cites W2044171986 @default.
• W1791492057 cites W2047923270 @default.
• W1791492057 cites W2049090024 @default.
• W1791492057 cites W2049728968 @default.
• W1791492057 cites W2052202348 @default.
• W1791492057 cites W2056841403 @default.
• W1791492057 cites W2057132224 @default.
• W1791492057 cites W2058713081 @default.
• W1791492057 cites W2060634108 @default.
• W1791492057 cites W2061081202 @default.
• W1791492057 cites W2062124103 @default.
• W1791492057 cites W2062350167 @default.
• W1791492057 cites W2066416002 @default.
• W1791492057 cites W2066580767 @default.
• W1791492057 cites W2066588666 @default.
• W1791492057 cites W2067000030 @default.
• W1791492057 cites W2067970495 @default.
• W1791492057 cites W2070619672 @default.

• next